CD274 and neoplasm: These cohorts encompassed distinct but clinically relevant immunotherapy settings, including anti–PD-L1–based and anti–PD-1–based regimens, administered as monotherapy or in combination with lenvatinib, with tumor samples collected at different clinical time points.